Dr. Jim Tananbaum is the founder and CEO of Foresite Capital and an industry leader with twenty-five years of healthcare entrepreneurial and investing experience. Dr. Tananbaum focuses on strategic, operational and financial opportunities to build franchise healthcare businesses. He has been the chief architect of Foresite Capital’s investment organization structure and investment strategy and has played a significant role in numerous Foresite Capital portfolio companies.
Prior to founding Foresite Capital, Dr. Tananbaum co-founded two leading biopharmaceutical companies and two healthcare investment practices. While finishing Harvard University Medical and Business Schools and earning an MS from the Massachusetts Institute of Technology, he founded GelTex Pharmaceuticals, which brought two drugs to market for less than $80 million. GelTex was acquired in 1998 for $1.6 billion, when its lead drug, Renagel (Renzela) had an annual revenue run rate in excess of $200 million. Today, Renzela is estimated to produce close to $1 billion in annual revenue, twenty-two years after its launch. Dr. Tananbaum also co-founded and was CEO of Theravance, Inc. who share GSK’s respiratory franchise through a joint venture, Innoviva, and completed a spin-off, Theravance Biopharma, Inc.
Dr. Tananbaum graduated with a B.S. and B.S.E.E. from Yale University, an M.D. from Harvard Medical School, an M.S. from MIT and an M.B.A from Harvard Business School. He has served on the advisory boards and visiting committees to the Harvard-MIT HST program and on Yale’s President Advisory Counsel.